Taking psilocybin for science
October 10, 2022 DOI: 10.54377/d188-22e2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort |
|---|---|
| Sample size | 60 |
| Population | Healthy volunteers |
| Intervention | Psilocybin |
| Topics | Psilocybin |
| Keywords | Hallucinogen |
| Key findings | Brain scans of healthy volunteers during a psilocybin experience reveal neural changes that may inform mental health treatment development. |
Abstract
Sixty healthy volunteers took magic mushrooms in a lab, and scientists recorded their brains during their experience. Approximately half of the Australian population will experience a mental health disorder during their lifetime, and scientists are turning to an unlikely place in the search for treatment. Researchers at Monash University are scanning the brains of healthy […]
Comparable studies
Other observational and cohort studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression | 2017 | Observational cohort | n = 19 |
| Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Healthy volunteers | 2019 | Observational cohort | n = 8 |
| Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin Humans | 2017 | Observational study | |
| Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. USA adult respondents from the National Survey on Drug Use and Health (2008-2012) | 2015 | Observational cohort | n = 190,000 |
| Prediction of Psilocybin Response in Healthy Volunteers Healthy volunteers | 2012 | Observational cohort | n = 409 |